2026-06-05T21:43:12Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/372232026-02-03T10:50:40Zcom_10630_2254col_10630_37953

00925njm 22002777a 4500 dc Hanna, Catherine R. author Robles-Zurita, José Antonio author Briggs, Andrew author Harkin, Andrea author Kelly, Caroline author McQueen, John author Allan, Karen author Pearson, Sarah author Hollander, Henrik author Glimelius, Bengt author Salazar, Ramon author Segelov, Eva author Saunders, Mark author Iveson, Tim author Jones, Robert J. author Boyd, Kathleen A. author 2021 Background: The Short Course Oncology Treatment (SCOT) trial demonstrated non-infer ior it y, less toxicit y, and cost- effectiveness from a UK perspective of 3 versus 6 months of oxaliplatin-based chemotherapy for patients with colorectal cancer. This study assessed the cost-effectiveness of shorter treatment and the budget impact of implementing trial findings from the perspectives of all countries recruited to SCOT: Australia, Denmark, New Zealand, Spain, Sweden, and the United Kingdom. Patients and Methods: Individual cost–utility analyses were performed from the perspective of each country. Resource, quality of life, and survival estimates from the SCOT trial ( N = 6065) were used. Probabilistic sensitivity analysis and subgroup analyses were undertaken. Using undiscounted costs from these cost–utility analyses, the impact on country-specific healthcare budgets of implementing the SCOT trial findings was calculated over a 5- year period. The currency used was US dollars (US$), and 2019 was the base year. One-way and scenario sensitivity analysis addressed uncertainty within the budget impact analysis. Results: Three months of treatment were cost saving and cost-effective compared to 6 months from the perspective of all countries. The incremental net monetary benefit per patient ranged from US$8972 (Spain) to US$13,884 (Denmark). The healthcare budget impact over 5 years for the base-case scenario ranged from US$3.6 million (New Zealand) to US$61.4 million (UK) and totaled over US$150 million across all countries. Conclusion: This study has widened the transferability of results from the SCOT trial, showing that shorter treatment is cost-effective from a multi-country perspective. The vast savings from implementation could fully justify the investment in conducting the SCOT trial. Hanna, C. R., Robles-Zurita, J. A., Briggs, A., Harkin, A., Kelly, C., McQueen, J., ... & Boyd, K. A. (2021). Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clinical colorectal cancer, 20(3), 236-244. https://hdl.handle.net/10630/37223 10.1016/j.clcc.2021.04.001 Cancer - Tratamiento Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis